GI
Gilead Sciences
GILD·NASDAQFoster City CAFounded 198717,000 employees
Large CapbiotechPublicVirologyOncologyImmunology
Platform: SM & Cell
Market Cap
$105B
All Drugs
14
Clinical Trials
24
Failed / Terminated
4
FDA Approved
2
Stock Price & Catalysts (GILD)
Loading GILD stock data...
Drug Pipeline (14 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| Zanuratamab | GIL-1286 | Phase 1/2 | 1 | CDK2 | BCCParkinson's | ||
| GIL-9779 | GIL-9779 | Phase 1 | 1 | IL-17A | MDDRCC | ||
| GIL-2445 | GIL-2445 | Phase 2/3 | 1 | PSMA | PsATTR Amyloidosis | ||
| Talalemzoparlimab | GIL-2749 | Phase 1 | 2 | FcRn | RAACC | ||
| Voxacagene | GIL-587 | Phase 2/3 | 1 | SOS1 | IgAN | ||
| GIL-9227 | GIL-9227 | Phase 2/3 | 1 | GPRC5D | PBC | ||
| GIL-2011 | GIL-2011 | Preclinical | 2 | VEGF | Heart Failure | ||
| GIL-9142 | GIL-9142 | Phase 1 | 2 | FXIa | EoE | ||
| GIL-6239 | GIL-6239 | Phase 2 | 2 | TNFα | GIST | ||
| GIL-4361 | GIL-4361 | Preclinical | 1 | PCSK9 | Gastric CaHNSCC | ||
| Semainavolisib | GIL-756 | Phase 2 | 2 | PARP | WM | ||
| GIL-2037 | GIL-2037 | Approved | 3 | KRASG12D | CLLLN | ||
| GIL-8529 | GIL-8529 | Phase 1/2 | 1 | JAK1 | AMLOvarian Ca | ||
| GIL-2259 | GIL-2259 | Approved | 4 | SMN2 | ET |
SEC Filings & Financial Documents
Insider Trading Activity
Fetching insider trading data from SEC EDGAR...
Catalyst Events (17)